Investment (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Investment (Details) [Line Items]
Fair market value			$ 491
Recognized finance gain (loss)	$ 137	$ 243	317	$ 654
Foreign exchange gain (loss)	$ 13	$ 28	$ 37	$ 36
Lantern Pharma Inc [Member]
Investment (Details) [Line Items]
Common shares (in Shares)			43,898

The amount of net gains or losses on foreign currency cash flow hedges reclassified during the period to earnings from accumulated other comprehensive income upon the hedged transaction affecting earnings.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959

Name:	us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration